Kevin O. Mcnerney

Hematology | Oncology
225 E Chicago Ave
Chicago, IL 60611

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications

HLH-like syndromes associate with increased risk of death and CD19-negative relapse post-CAR T in pediatric B-ALL.

HLH-like syndromes associate with increased risk of death and CD19-negative relapse post-CAR T in pediatric B-ALL.

Journal: Blood advances
Published: March 24, 2026

The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.

The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.

Journal: Nature reviews. Clinical oncology
Published: December 15, 2025

How I treat HLH-like toxicities after immune effector cell therapy.

How I treat HLH-like toxicities after immune effector cell therapy.

Journal: Blood
Published: November 07, 2025

Erratum to 'Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome'[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9].

Erratum to 'Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome'[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9].

Journal: Transplantation and cellular therapy
Published: October 09, 2025

Management Practices of CAR T-cell-Related Inflammatory Toxicities: A Survey of Pediatric CAR T-cell Providers.

Management Practices of CAR T-cell-Related Inflammatory Toxicities: A Survey of Pediatric CAR T-cell Providers.

Journal: Transplantation and cellular therapy
Published: July 06, 2025

Harmonization on defining B-cell recovery post CD19-CAR T-cell therapy in B-cell acute lymphoblastic leukemia: An international consensus statement.

Harmonization on defining B-cell recovery post CD19-CAR T-cell therapy in B-cell acute lymphoblastic leukemia: An international consensus statement.

Journal: HemaSphere
Published: June 09, 2025

Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel.

Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel.

Journal: Blood advances
Published: April 29, 2025

Consensus recommendations for early critical care management of paediatric HCT and IEC recipients: what comes next?

Consensus recommendations for early critical care management of paediatric HCT and IEC recipients: what comes next?

Journal: The Lancet. Child & adolescent health
Published: April 20, 2025

Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel.

Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel.

Journal: Blood advances
Published: April 14, 2025

Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry.

Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry.

Journal: Blood advances
Published: January 28, 2025

Tisagenlecleucel in Practice: Real-World Lessons in Pediatric and Young Adult B-ALL.

Tisagenlecleucel in Practice: Real-World Lessons in Pediatric and Young Adult B-ALL.

Journal: Transplantation and cellular therapy
Published: October 31, 2024

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy.

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy.

Journal: Blood advances
Published: September 20, 2024
Showing 1-12 of 40

Last Updated: 09/26/2026